Literature DB >> 18330696

The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study.

Anne E Cust1, Tanja Stocks, Annekatrin Lukanova, Eva Lundin, Göran Hallmans, Rudolf Kaaks, Håkan Jonsson, Pär Stattin.   

Abstract

It is hypothesized that insulin resistance and related metabolic factors may influence breast cancer risk, however the epidemiological evidence remains inconclusive. We conducted a case-control study nested in a prospective cohort in Northern Sweden, to clarify the associations of body mass index (BMI), leptin, adiponectin, C-peptide, and glycated haemoglobin (HbA1c) with breast cancer risk. We also investigated whether these associations may be modified by age at diagnosis, tumour stage, and oestrogen and progesterone receptor status. During follow-up, 561 women developed invasive breast cancer and 561 matched controls were selected. Conditional logistic regression was used to calculate odds ratios (OR) as estimates of relative risk, and 95% confidence intervals (CI). The associations of BMI, leptin and HbA1c with breast cancer risk differed significantly according to whether the tumour was diagnosed as stage I or stage II-IV (P (heterogeneity) all <0.05). These factors were significantly inversely associated with risk in the group of stage I tumours, with ORs for top vs. bottom tertile for BMI of 0.48 (95% CI, 0.30-0.78, P (trend) = 0.004); leptin, 0.64 (95% CI, 0.41-1.00, P (trend) = 0.06); and HbA1c, 0.47 (95% CI, 0.28-0.80, P (trend) = 0.005). For stage II-IV tumours, there was a suggestion of an increased risk with higher levels of these factors. There were no significant differences in the associations of BMI, leptin, adiponectin, C-peptide and HbA1c with breast cancer risk in subgroups of age at diagnosis or tumour receptor status. This prospective study suggests that BMI, leptin and HbA1c influence breast tumour initiation and progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18330696     DOI: 10.1007/s10549-008-9958-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  35 in total

1.  Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.

Authors:  Debora Macis; Sara Gandini; Aliana Guerrieri-Gonzaga; Harriet Johansson; Paolo Magni; Massimiliano Ruscica; Matteo Lazzeroni; Davide Serrano; Massimiliano Cazzaniga; Serena Mora; Irene Feroce; Maria Pizzamiglio; Maria Teresa Sandri; Marcella Gulisano; Bernardo Bonanni; Andrea Decensi
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications.

Authors:  Antonio Macciò; Clelia Madeddu; Giulia Gramignano; Carlo Mulas; Carlo Floris; Daniela Massa; Giorgio Astara; Paola Chessa; Giovanni Mantovani
Journal:  J Mol Med (Berl)       Date:  2010-03-26       Impact factor: 4.599

Review 3.  Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.

Authors:  Mark F Munsell; Brian L Sprague; Donald A Berry; Gary Chisholm; Amy Trentham-Dietz
Journal:  Epidemiol Rev       Date:  2014       Impact factor: 6.222

Review 4.  Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis.

Authors:  Debora Macis; Aliana Guerrieri-Gonzaga; Sara Gandini
Journal:  Int J Epidemiol       Date:  2014-04-15       Impact factor: 7.196

5.  Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women?

Authors:  Mia M Gaudet; Roni T Falk; Gretchen L Gierach; James V Lacey; Barry I Graubard; Joanne F Dorgan; Louise A Brinton
Journal:  Cancer Epidemiol       Date:  2010-06-26       Impact factor: 2.984

6.  Type 2 diabetes and obesity in midlife and breast cancer risk in the Reykjavik cohort.

Authors:  Gertraud Maskarinec; Álfheiður Haraldsdóttir; Kristjana Einarsdóttir; Thor Aspelund; Laufey Tryggvadóttir; Tamara B Harris; Vilmundur Gudnason; Jóhanna E Torfadóttir
Journal:  Cancer Causes Control       Date:  2019-08-10       Impact factor: 2.506

7.  Obesity-related markers and breast cancer in CPS-II Nutrition Cohort.

Authors:  Mia M Gaudet; Alpa V Patel; Lauren R Teras; Juzhong Sun; Peter T Campbell; Victoria L Stevens; Eric J Jacobs; Susan M Gapstur
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

8.  Plasma C-peptide, mammographic breast density, and risk of invasive breast cancer.

Authors:  Thomas P Ahern; Susan E Hankinson; Walter C Willett; Michael N Pollak; A Heather Eliassen; Rulla M Tamimi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10       Impact factor: 4.254

9.  Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues.

Authors:  Ben-Dong Chen; Wen-Chao Zhao; Jian-Da Dong; Hui Sima
Journal:  Mol Biol Rep       Date:  2014-02-28       Impact factor: 2.316

10.  The relation of leptin and adiponectin with breast density among premenopausal women.

Authors:  Gertraud Maskarinec; Christy Woolcott; Jana S Steude; Adrian A Franke; Robert V Cooney
Journal:  Eur J Cancer Prev       Date:  2010-01       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.